Novartis’s Pelacarsen Exit: Biotech’s 2026 Shift
Novartis dropped pelacarsen. See why biotech investors are now eyeing gene editing and RNAi for cardiovascular drugs in 2026.
Novartis dropped pelacarsen. See why biotech investors are now eyeing gene editing and RNAi for cardiovascular drugs in 2026.
Why could FFAI stock jump? Faraday Future's Q2 2026 production efficiency rose 15%, with $100M financing. See what's next for FF 91 deliveries.
US & Canadian job data just rocked forex markets. See how 280,000 new US jobs impact 2026 interest rates for both countries.
Deepfake weapon specs are a global security risk by 2026. See how AI authenticity and deepfake detection can counter this defense intelligence threat.
Boost savings with 4.5% APY zero-cost accounts in 2026. Learn how to find high-yield options without fees or minimums. See why it matters.
Cyber warfare could cost global economies trillions by 2027. Learn why critical infrastructure is targeted & what's needed to prepare.
AI could raise global financial literacy by 15%, closing a major gap. Personalized learning and AI tools make expert advice accessible.
SIPRI reports record $2.44T military spend on AI. See how over 30 nations risk AI proliferation and what's needed to control autonomous weapons.
AGI will be a $68B market by 2030. See how it changes jobs, supply chains, and regulations like the EU's AI Act. Get ready for major shifts.
Why Iran's energy sector FDI is collapsing. Protests, instability, and sanctions make 2027 investment unlikely. See key risks.